

Comparative Profit and Loss and Balance Sheet information

Key figures EUR million	2025 Restated	2025	2024 Restated	2024
Invoicing	4,201.2	4,201.2	3,771.8	3,771.8
Net Sales	201.6	1,906.2	200.0	1,679.7
Adjusted EBITDA	35.1	35.1	33.4	33.4
EBITDA	20.3	20.3	27.2	27.2
Adjusted EBITDA %	17.4	1.8	16.7	2.0
EBITDA %	10.1	1.1	13.6	1.6
Profit for the period	-27.2	-27.2	-20.1	-20.1
Earnings per share, EUR	-0.15	-0.15	-0.11	-0.11
Net cash flow from operating activities	60.0	60.0	38.7	38.7
Free cash flow	58.4	58.4	43.4	43.4
Gearing, %	-81.4	-81.4	-28.0	-28.0
Equity ratio, %	13.1	10.8	18.7	15.4
Return on capital employed (ROCE), %	1.3	1.3	5.4	5.4
Numbers above include dose dispensing Sweden				
Net Sales	6.0	6.0	21.7	21.7
Adjusted EBITDA	0.2	0.2	0.1	0.1
EBITDA	-2.5	-2.5	1.6	1.6

Balance sheet EUR million	2025 Restated	2025	2024 Restated	2024
Non-current assets total	289.3	289.3	314.0	314.0
Current assets				
Inventories	5.5	188.5	5.3	176.3
Trade receivables	311.7	311.7	247.1	247.1
Income tax receivable	1.1	1.1	-	-
Other receivables	18.6	3.4	27.9	11.7
Cash and cash equivalents	152.2	152.2	113.5	113.5
Assets held for sale	-	-	13.1	13.1
Current assets total	489.1	656.9	406.8	561.6
Assets total	778.4	946.1	720.8	875.6

EUR million	2025 Restated	2025	2024 Restated	2024
Equity attributable to the parent company stakeholders	100.8	100.8	133.4	133.4
Non-Current liabilities total	55.2	55.2	54.7	54.7
Current liabilities				
Trade payables	558.0	725.7	471.4	626.2
Interest-bearing liabilities	31.7	31.7	36.4	36.4
Income tax payables	0.0	0.0	0.3	0.3
Other current liabilities	32.6	32.6	22.9	22.9
Liabilities related to assets held for sale	-	-	1.8	1.8
Current liabilities total	622.3	790.1	532.8	687.6
Equity and liabilities total	778.4	946.1	720.8	875.6